AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Synagis (palivizumab) — Europe product sales by Year
Synagis (palivizumab) — Europe product sales ($M) ($M)
AstraZeneca Synagis (palivizumab) — Europe product sales: $50M in FY2025, down 56.9% from a year earlier.
Where the FY2025 figure comes from
“|| Synagis | 292 | (35) | (34) | (3) | (57) | 214 | 2 | 4 | 50 | (56) | (57) | 31 | (76) | (76)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Synagis (palivizumab) — Europe product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50 | -56.9% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 116 | -33.7% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 175 | -17.8% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 213 | +4.9% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 203 | -37.5% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 325 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up synagis (palivizumab) — Europe product sales
Cite this data
StockData. (2026). AstraZeneca Synagis (palivizumab) — Europe product sales ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-synagis-eu
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.